Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BioCardia ( (BCDA) ) has provided an announcement.
On September 22, 2025, BioCardia announced a positive preliminary clinical consultation with Japan’s PMDA regarding the CardiAMP Heart Failure Trial results. This meeting was a preparatory step for a formal consultation on the clinical data’s acceptability for approval submission. The PMDA requested additional information on various aspects of the trial, and BioCardia plans to address these queries before a formal consultation later in the year. This development could potentially enhance BioCardia’s position in the market by enabling access for patients with significant therapeutic needs.
The most recent analyst rating on (BCDA) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on BioCardia stock, see the BCDA Stock Forecast page.
Spark’s Take on BCDA Stock
According to Spark, TipRanks’ AI Analyst, BCDA is a Neutral.
BioCardia’s overall stock score is primarily impacted by its weak financial performance and bearish technical indicators. The negative valuation metrics further weigh down the score. While the earnings call highlighted some positive developments in clinical trials and regulatory progress, the financial challenges and market sentiment remain significant concerns.
To see Spark’s full report on BCDA stock, click here.
More about BioCardia
BioCardia, Inc., headquartered in Sunnyvale, California, is a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. The company develops biotherapeutic platforms including CardiAMP autologous and CardiALLO allogeneic cell therapies, supported by its Helix biotherapeutic delivery and Morph vascular navigation product platforms.
Average Trading Volume: 653,590
Technical Sentiment Signal: Sell
Current Market Cap: $6.74M
See more insights into BCDA stock on TipRanks’ Stock Analysis page.